You are currently viewing our site as a guest, which gives you limited access to our site features. By signing up for a free membership, you will receive our Investment Opportunity newsletters and have access to additional features for finding and comparing managed funds and shares. Registration is fast and simple, so please:
Business Description: Universal Biosensors Inc. (UBI) is a specialist medical diagnostics company focusing on research, development, manufacture and commercialisation of in vitro diagnostic devices for consumer and professional point of care use. UBI has developed a blood glucose monitoring product that is being commercialised globally by LifeScan, Inc. a Johnson & Johnson company.
Strategy Analysis: UBI's strategy involves: manufacturing blood glucose test strips for LifeScan; providing post market support services to LifeScan in connection with the blood glucose test; continuing to undertake contract research and development work on behalf of LifeScan and seeking to develop additional products in the field of diabetes and blood glucose monitoring for LifeScan; extending the electrochemical cell technology by developing new non-blood glucose tests and; entering into collaborative arrangements or strategic alliances with other life sciences companies or other industry participants to complete the development and commercialisation of UBI's non-blood glucose tests.
Universal Biosensors reported net loss of $9.13m for the year ended 31 December 2012. Revenue from ordinary activities were $29.65m. Basic and Diluted EPS were (5.7) cents compared to (9) cents last year. The net operating cash outflow was $3.3m compared to an outflow of $7.16m in the pcp. No dividend was declared.
Nick Swales, Regional Director, Newcastle Office, Rathbones 27/10/2014 |
â€śIf you want to have a better performance than the crowd, you must do things differently from the crowd.â€ť Sir John Templeton.
Ric Spooner (Chief Market Analyst, CMC Markets) 20/10/2014 |
Today, Australian investors will not have to go it alone buying stocks as they did for much of last week. Bargain hunters this morning will be supported by the morale boosting encouragement of a 3% turnaround in the German Dax and a 264 point rally in the Dow Jones.
Carl Richards, director of investor education at the BAM Alliance 17/10/2014 |
â€śAs odd as it may sound, the sooner you start treating your investments like you treat life, the happier youâ€™ll be with the outcome.â€ť
William H. Gross, Janus Capital Group 16/10/2014 |
â€śFinancial markets are artificially priced. In the bond market, there is nothing normal about a three year German Bund yielding â€śminusâ€ť 10 basis points.â€ť
CMC Markets 8/10/2014 |
Share market indices around the globe are breaking down. While analysts cast around for reasons, itâ€™s clear that a time factor is in play. Simply put, many investors â€śfeelâ€ť a correction is overdue. How low could it go?
The Age 19/12/2013 |
Ten Network's programming ambitions will be funded by a $200 million loan guaranteed by three of its billionaire owners, as the free-to-air broadcaster declared digital was the future and pointed to early signs that its switch to an older market demographic was working.
IMPORTANT: This information has been prepared without taking into account your objectives, financial situation or needs and you should consider if the information is appropriate for you before making an investment decision. Neither InvestSMART Financial Services Pty Ltd nor any of its Related Companies make any recommendations as to the merits of any investment opportunity referred to in its emails or its related websites. Product disclosure statements for financial products offered through InvestSMART can be downloaded from this website or obtained by contacting 1300 880 160. You should consider the product disclosure statement before making a decision about the product. All indications of performance returns are historical and can not be relied upon as an indicator for future performance.